Core Insights - The company has confirmed that its HMO (Human Milk Oligosaccharides) product is in the trial production phase, with a capacity of 260 tons per year [2] - The company has received approval for various production strains from the National Health Commission, indicating progress in regulatory compliance [2] - The company is actively establishing connections with major dairy product clients and has entered the qualification process to become a supplier for leading companies in the industry [2] Production and Sales - The first phase of the production project has commenced trial production, with steady progress in all production stages [2] - The company is focusing on market expansion and has initiated contact with key target customers [2] Research and Development - Multiple production strains have been submitted for approval, which has been accepted by the relevant health authorities [2]
朗坤科技：目前朗健生物一期年产260 吨项目已进入试生产阶段，各项生产环节正稳步推进